Search results for "Dopamine Prodrug"
showing 4 items of 4 documents
A new dopamine amino-acid conjugate: preclinical in vitro studies and evaluation of behavioural effects in rats
2012
It is well established that alterations in the functionality of dopaminergic transmission are associated with neurodegenerative diseases such as Parkinson’s Disease. The purpose of this study was to investigate the activity of a new dopamine amino-acid conjugate: L-phenylalanine-β-(3,4-dihydroxyphenyl) etilamide(DA-Phe) in the central nervous system, by assessing its influence on different behavioural parameters in the rat. Preliminarily, we tested the in vitro stability in plasmatic environment following the disappearance of DA-Phen from human plasma and the concurrent appearance of dopamine. Using rat brain homogenate, we also evaluated the level of DA-Phen cleavage by cerebral enzymes an…
Potential dopamine prodrug-loaded liposomes: preparation, characterization, andin vitrostability studies
2010
Dopamine delivery to the central nervous system (CNS) undergoes the permeability limitations of the blood-brain barrier (BBB). Condensation of dopamine with neutral amino acids could afford potential pro- drugs able to interact with the BBB endogenous transporters and easily enter the brain. To improve the bio-availability of the dopamine prodrug, 2-amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (DOPH), it was encapsulated in unilamellar liposomes of dimiristoylphosphatidylcholine (DMPC)and cholesterol. Vesicles were characterized by dynamic light scattering in order to evaluate their dimensions and vesicle stability, by zeta-potential measurements, by means of electronic mi…
Evaluation of the aptitude to cross the BBB of a new dopamine aminoacidic prodrug
2012
One of the most important factors limiting the development of new drugs for the CNS is the ability to cross the BBB which is a barrier that controls the entrance and exit of both endogenous and exogenous compounds. BBB expresses several transport systems that carry actively into the brain important nutrients (e.g. glucose and amino acids) and are able to import or export various xenobiotics including drugs and their metabolites. The content of active in the brain depends on the overall difference between the drug uptake and drug efflux processes [1]. Dopamine (DA) is a crucial neurotransmitter; its striatal depletion is responsible of clinical signs of Parkinson’s disease (PD). Owing to the…
Synthesis and in vitro studies on a potential dopamine prodrug.
2008
Dopamine delivery to the central nervous system (CNS) undergoes the permeability limitations of blood-brain barrier (BBB) which is a selective interface that excludes most water-soluble molecules from entering the brain. Neutral amino acids permeate the BBB by specific transport systems. Conden- sation of dopamine with neutral amino acids could afford potential prodrugs able to interact with the BBB endogenous transporters and easily enter the brain. The synthesis and characterization of the dopamine derivative 2-amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (7) is de- scribed. The chemical and enzymatic stability of 7 was evaluated. The molecular weight (300 Da) and Log P …